Is Healthcare Reform Socialism?

Erik Greb PharmTech editorThe dust has partly settled since President Obama signed the “Health Care and Education Affordability Reconciliation Act of 2010.” By now, analysts have had a chance to examine the act’s details and get a sense of what practical effects the legislation will have. So what will healthcare reform mean for pharmaceutical manufacturers? Read more »

Strutting and Fretting about Healthcare Reform

Erik Greb PharmTech editorAfter much ado, the US House of Representatives passed a healthcare-reform bill this weekend. Drugmakers and commentators are understandably eager to parse the bill to find out what it would mean for the pharmaceutical and biopharmaceutical industries. So what’s the verdict? Read more »

BIO–1, GPhA–0

Erik Greb PharmTech editorThe Biotechnology Industry Organization (BIO) has won the latest battle over follow-on biologics. Last week, the House Energy and Commerce Committee approved Rep. Anna Eshoo’s (D-CA) amendment to the America’s Affordable Health Choices Act (H.R. 3200). The Eshoo amendment, a regulatory pathway for the approval of biosimilars, would grant about 12 years of market exclusivity to each new biological medicine. Read more »

Chutes, Ladders, and Healthcare Reform

Erik Greb PharmTech editorCongress has taken up the Obama administration’s goal of making healthcare more affordable by introducing various strategies for reducing the cost of prescription drugs. But the Pharmaceutical Research and Manufacturers of America and the Biotechnology Industry Organization (BIO) have resisted several of Congress’s initiatives, and cost control has been elusive so far. Read more »

Don’t Delay Affordable Healthcare

Erik Greb PharmTech editorPresident Obama’s plan for lowering the cost of healthcare relies partly on ensuring that affordable generic drugs are available to patients. This strategy is not likely to be palatable to innovator companies, who have tried various ways of delaying generic drugs’ introduction to the market. Read more »

Restrategizing Is No Longer an Option

Angie Drakulich PharmTech editorSo far, the first quarter of 2009 has been full of initiatives that call for, if not push for, change in the pharmaceutical industry and in medical science overall. Some may say it started when Obama took office. Within six weeks of leading the country, he announced $1.1 billion for comparative effectiveness research. Then, his proposed FY 2010 budget included support for a regulatory pathway for follow-on biologics. And this week, he reversed the ban on the use of federal funding for stem-cell research.

Read more »

To Lead, You Need Followers

Erik Greb PharmTech editorThe wait may soon be over for US Food and Drug Administration employees wondering who their new boss will be. President Obama is expected to introduce Governor Kathleen Sebelius of Kansas today as his new nominee for secretary of the US Department of Health and Human Services. Read more »

Obama’s Speech Was Meant for Pharma Too

Angie Drakulich PharmTech editorNo doubt millions were moved by President Barack Obama’s inauguration speech yesterday. Having listened to and read it several times, it occurred to me that many of his messages apply directly to our industry. Read more »

Helping Patients in Dire Financial Straits

Erik Greb PharmTech editorPharmaceutical Technology focuses much of its attention on the companies that manufacture the world’s drugs. We’ve noticed many stories on the wires lately that describe how the current economic situation is hurting drugmakers. But several press releases I saw today reminded me that patients are experiencing difficult times, too. Read more »

Who Will Lead at FDA?

Patricia Van Arnum PharmTech editor As the pieces of President-Elect Barack Obama’s administration fall into place, one looming choice of great importance to the pharmaceutical and biotechnology industries is the choice of the next commissioner of the US Food and Drug Administration. A recent article in the Wall Street Journal (WSJ) put forth speculation on possible candidates for the top post. Read more »

« Previous PageNext Page »